SCHEMBL2200107

SCHEMBL2200107

NCCNC(CO)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAN2A1 Q16706 3/20 0.46
MAN1B1 Q9UKM7 3/20 0.46
MAN2B1 O00754 3/20 0.44
EPHX2 P34913 2/20 0.42
HRH1 P35367 2/20 0.42
MTOR P42345 1/20 0.42
RAB9A P51151 1/20 0.42
GRM7 Q14831 1/20 0.42
RIPK1 Q13546 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ADRB2 P07550 1/20 0.40
HTR2A P28223 2/20 0.40
TAAR1 Q96RJ0 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
EGFR P00533 1/20 0.40
AURKA O14965 2/20 0.38
RPS6KB1 P23443 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132858 1.00 MAN2A1 (0.46) MAN2A1MAN1B1MAN2B1EPHX2HRH1
SCHEMBL1132547 1.00 MAN2A1 (0.46) MAN2A1MAN1B1MAN2B1EPHX2HRH1
SCHEMBL258306 0.84 MAN2A1 (0.49) MAN2A1MAN1B1MAN2B1EPHX2MTOR
SCHEMBL11425422 0.81 HRH1 (0.42) EPHX2HRH1MTORRAB9AGRM7
SCHEMBL27668096 0.81 MAN2A1 (0.46) MAN2A1MAN1B1MAN2B1EPHX2MTOR
SCHEMBL8549011 0.81 RIPK1 (0.49) MAN2A1MAN1B1MAN2B1EPHX2MTOR
SCHEMBL8549178 0.81 RIPK1 (0.49) MAN2A1MAN1B1MAN2B1EPHX2MTOR
SCHEMBL8545776 0.81 RIPK1 (0.49) MAN2A1MAN1B1MAN2B1EPHX2MTOR
SCHEMBL4915574 0.79 L3MBTL1 (0.51) HRH1MTORRAB9AGRM7CYP3A4
SCHEMBL24505282 0.78 SMN1; SMN2 (0.50) MAN2A1MAN1B1MAN2B1EPHX2MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981958-B2 Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use INSTITUTO MEXICANO DEL PETROLEO (MX) 2018-05-29 US disclosed
US-9221803-B2 Asphaltene-dispersing/inhibiting additive based on oxazolidines derived from polyalkyl or polyalkenyl N-hydroxyalkyl succinimides INSTITUTO MEXICANO DEL PETROLEO (MX) 2015-12-29 US disclosed
US-20110162558-A1 Formulations comprising an asphaltene-dispersing/inhibiting additive based on oxazolidines derived from polyalkyl or polyalkenyl N-hydroxyalkyl succinimides INSTITUTO MEXICANO DEL PETROLEO (MX) 2011-07-07 US disclosed
US-20100107478-A1 Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use INSTITUTO MEXICANO DEL PETROLEO (MX) 2010-05-06 US disclosed
US-4223138-A VAPORIZATION, CONDENSATION, RETARDING FLOW TO REACTION ZONE BAYER AKTIENGESELLSCHAFT (DE) 1980-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100107478-A1 Oxazolidines derived from polyalkyl or polyalkenyl n-hydroxyalkyl succinimides, obtainment process and use HRH4, OGDH, HRH3 MAN2A1 4711/4885MAN1B1 4186/4885MAN2B1 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.